• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

隔离所需人数——一种新的群体健康指标,用于量化传染病隔离干预措施所带来的传播减少情况。

Number needed to isolate - a new population health metric to quantify transmission reductions from isolation interventions for infectious diseases.

作者信息

Prosser Aaron, Helfer Bartosz, Streiner David L

机构信息

Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.

Meta Research Centre, University of Wrocław, Wrocław, Poland.

出版信息

Popul Health Metr. 2024 Dec 23;22(1):39. doi: 10.1186/s12963-024-00360-y.

DOI:10.1186/s12963-024-00360-y
PMID:39716280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11668099/
Abstract

BACKGROUND

We have previously developed and reported on a procedure for estimating the purported benefits of immunity mandates using a novel variant of the number needed to treat (NNT) which we called the number needed to isolate (NNI). Here we demonstrate its broader properties as a useful population health metric.

MAIN BODY

The NNI is analogous to the number needed to treat (NNT = 1/ARR), except the absolute risk reduction (ARR) is the absolute transmission risk in a specific population. The NNI is the number of susceptible hosts in a population who need to be isolated to prevent one transmission event from them. The properties and utility of the NNI were modeled using simulated data and its model predictions were validated using real world data. The properties of the NNI are described for three categories of data from a previous study on transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): (1) in different settings, (2) after a specific exposure and (3) depending on symptomaticity status of susceptible hosts.

CONCLUSIONS

We provide a demonstration of the utility of the NNI as a valuable population health metric to quantify the transmission reductions from isolation interventions.

摘要

背景

我们之前开发并报告了一种程序,该程序使用一种新型的治疗所需人数(NNT)变体来估计免疫授权的所谓益处,我们将其称为隔离所需人数(NNI)。在此,我们展示了它作为一种有用的人群健康指标的更广泛特性。

主体内容

NNI类似于治疗所需人数(NNT = 1/ARR),不同之处在于绝对风险降低率(ARR)是特定人群中的绝对传播风险。NNI是人群中需要被隔离以防止其中一人引发一次传播事件的易感宿主数量。使用模拟数据对NNI的特性和效用进行了建模,并使用实际数据对其模型预测进行了验证。针对先前一项关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)传播性的研究中的三类数据描述了NNI的特性:(1)在不同环境中,(2)在特定暴露之后,以及(3)取决于易感宿主的症状状态。

结论

我们证明了NNI作为一种有价值的人群健康指标的效用,可用于量化隔离干预措施带来的传播减少情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f35/11668099/3d11fc5f694b/12963_2024_360_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f35/11668099/3d11fc5f694b/12963_2024_360_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f35/11668099/3d11fc5f694b/12963_2024_360_Fig1_HTML.jpg

相似文献

1
Number needed to isolate - a new population health metric to quantify transmission reductions from isolation interventions for infectious diseases.隔离所需人数——一种新的群体健康指标,用于量化传染病隔离干预措施所带来的传播减少情况。
Popul Health Metr. 2024 Dec 23;22(1):39. doi: 10.1186/s12963-024-00360-y.
2
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
3
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.
4
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Non-pharmacological measures implemented in the setting of long-term care facilities to prevent SARS-CoV-2 infections and their consequences: a rapid review.长期护理机构中实施的非药物措施以预防 SARS-CoV-2 感染及其后果:快速综述。
Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD015085. doi: 10.1002/14651858.CD015085.pub2.
7
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
8
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦片/利托那韦片组合包装用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
9
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
10
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.

本文引用的文献

1
Estimating the risk reduction of isolation on COVID-19 nonhousehold transmission and severe/critical illness in nonimmune individuals: September to November 2021.评估隔离措施对非免疫个体中新冠病毒非家庭传播以及严重/危重症的风险降低效果:2021年9月至11月
J Eval Clin Pract. 2023 Apr;29(3):438-446. doi: 10.1111/jep.13813. Epub 2023 Feb 8.
2
Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions.用于药物干预的基于治疗所需人数(NNT)的决策辅助工具的可获得性和使用情况。
Explor Res Clin Soc Pharm. 2021 Jun 24;2:100039. doi: 10.1016/j.rcsop.2021.100039. eCollection 2021 Jun.
3
Secondary attack rate of COVID-19 among contacts and risk factors, Tamil Nadu, March-May 2020: a retrospective cohort study.
2020年3月至5月,印度泰米尔纳德邦新冠病毒病密切接触者中的二代发病率及危险因素:一项回顾性队列研究
BMJ Open. 2021 Nov 5;11(11):e051491. doi: 10.1136/bmjopen-2021-051491.
4
Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis.亚洲获批的新冠疫苗及亚洲新冠疫苗接种计划的现状:批判性分析
Vaccines (Basel). 2021 Jun 4;9(6):600. doi: 10.3390/vaccines9060600.
5
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020.2020 年 5 月至 6 月印度全国血清学调查的 SARS-CoV-2 感染流行率。
Indian J Med Res. 2020;152(1 & 2):48-60. doi: 10.4103/ijmr.IJMR_3290_20.
6
Vaccines for Preventing Influenza in Healthy Individuals.用于预防健康个体流感的疫苗。
Acad Emerg Med. 2019 Jan;26(1):113-114. doi: 10.1111/acem.13668. Epub 2018 Dec 18.
7
When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.何时应使用有效治疗方法?治疗所需阈值数量和治疗最小事件发生率的推导。
J Clin Epidemiol. 2001 Mar;54(3):253-62. doi: 10.1016/s0895-4356(01)00347-x.
8
Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators.抗高血压药物治疗对男性和女性心血管结局的影响。来自随机对照试验个体患者数据的荟萃分析。INDANA研究人员。
Ann Intern Med. 1997 May 15;126(10):761-7. doi: 10.7326/0003-4819-126-10-199705150-00002.